ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis Sells 1,000 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares in the company, valued at $4,048,711.50. The trade was a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Krista Davis also recently made the following trade(s):

• On Friday, February 21st, Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00.
• On Wednesday, December 11th, Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00.

ANI Pharmaceuticals Price Performance

ANIP opened at $58.81 on Tuesday. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.81. The company’s 50 day simple moving average is $57.76 and its 200 day simple moving average is $58.09. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The stock has a market capitalization of $1.24 billion, a PE ratio of -106.93 and a beta of 0.63.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of ANI Pharmaceuticals by 41.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 47,899 shares of the specialty pharmaceutical company’s stock valued at $2,648,000 after acquiring an additional 13,948 shares during the period. Stonepine Capital Management LLC acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $1,128,000. Rafferty Asset Management LLC acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $200,000. ProShare Advisors LLC lifted its stake in ANI Pharmaceuticals by 29.0% during the fourth quarter. ProShare Advisors LLC now owns 6,532 shares of the specialty pharmaceutical company’s stock valued at $361,000 after buying an additional 1,469 shares in the last quarter. Finally, Nomura Holdings Inc. lifted its stake in ANI Pharmaceuticals by 1.5% during the fourth quarter. Nomura Holdings Inc. now owns 213,879 shares of the specialty pharmaceutical company’s stock valued at $11,823,000 after buying an additional 3,255 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on ANIP. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Guggenheim upped their target price on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target for the company. Finally, StockNews.com cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $79.00.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.